19937 results for «»
19937 results
LANDMARK RCT - Early outcomes of a randomised non-inferiority trial comparing TAVI devices: the LANDMARK trial
15 May 2024 – From EuroPCR 2024
This session provides an overview of the early outcomes of the LANDMARK trial, a randomized non-inferiority trial comparing TAVI devices. It examines baseline characteristics, the significance of intermediate sizes according to MSCT recommendations, real-world representative cases from the LANDMARK RCT, insights from quantitative aortography and echocardiography...
The future of STEMI care: a new treatment for bridging the gap from diagnosis to treatment
14 May 2024 – From EuroPCR 2024
Watch this session to delve into the crucial role of pre-hospital STEMI diagnosis and treatment. Gain insights into the significance of early intervention and explore previous facilitated PCI trials in STEMI. Additionally, learn about a promising new agent for pre-hospital STEMI treatment, offering potential advancements in...
How does the female heart respond to severe aortic stenosis and aortic intervention?
15 May 2024 – From EuroPCR 2024
In this session, gain insights into the gender-specific differences among patients with aortic stenosis (AS) and their implications for treatment strategies. Explore the significance of hemodynamics and durability from a patient's perspective, shedding light on the importance of personalized care. Engage in discussions about the optimal...
Drug-coated balloon PCI for de novo lesions: when and how?
15 May 2024 – From EuroPCR 2024
Michael Haude and Michael Lee discuss various aspects of DCB PCI, emphasizing lesion preparation, dissection management, and the role of imaging and physiology. They touch upon ongoing studies comparing DCB PCI with DES PCI, consider the duration of DAPT in ACS and non-ACS cases, and explore...
Rapid learning curve to TTVR with the Cardiovalve device
15 May 2024 – From EuroPCR 2024
Explore the discussion between Rodrigo Estevez Loureiro and Georg Nickenig on treating tricuspid regurgitation with the innovative Cardiovalve replacement therapy. Learn about the unique features and properties of this low-profile valve with a dual frame, and hear Estevez Loureiro share his firsthand experience using the TTVR...
The LANDMARK trial: early outcomes of a randomised non-inferiority trial comparing TAVI devices
15 May 2024 – From EuroPCR 2024
In this video, Christopher Cook interviews Patrick Serruys about the late-breaking clinical trial data from the LANDMARK RCT. Patrick Serruys begins by explaining the LANDMARK trial, which compares TAVI devices, and emphasizes the complexity of applying VARC-3 criteria. He highlights that the 30-day outcomes confirm the...
First report of an IDE pivotal study of a dedicated splitting device during TAVR
15 May 2024 – From EuroPCR 2024
Watch this interview in which Christopher Cook hosts Martin Leon to discuss pivotal study data on the ShortCut dedicated leaflet splitting device. They revisit the unmet clinical need for leaflet splitting during TAVR: transcatheter valve failures, noting that transcatheter valve failures could surpass surgical bioprosthetic valve failures...
The complexity in treatment of patients in shock
16 May 2024 – From EuroPCR 2024
This session is essential for those looking to analyze and discuss the findings of the DanGer shock randomized trial, explore the latest evidence in the ACS field such as Horizon, and implement evidence-based practices in peri-procedural planning, execution, drug administration, and weaning strategies to optimize outcomes...
Asymptomatic severe aortic stenosis, how will new evidence change our practice?
15 May 2024 – From EuroPCR 2024
Victoria Delgado and Martin Leon discuss how to treat patients with asymptomatic severe aortic stenosis at an earlier stage and how current trials may change our practice in the future and broaden the indications.
This interview was filmed at EuroPCR 2024: see more videos here.
NOTION-2: first TAVI vs. SAVR randomised trial in younger low-risk patients with severe tricuspid or bicuspid aortic valve stenosis
15 May 2024 – From EuroPCR 2024
Christopher Cook interviews Ole de Backer about this study he presented at EuroPCR 2024: It provides further data concerning the 1-year outcome of younger AS patients with tricuspid valve anatomy treated with TAVI compared to SAVR. TAVI and SAVR showed similar rates of the primary endpoint...
Learning from the Masters - Key learnings from 20 years of transcatheter edge-to-edge repair
15 May 2024 – From EuroPCR 2024
Maurizio Taramasso interviews Ottavio Alfieri, a pioneering figure in valve surgery and a key contributor to the development of transcatheter edge-to-edge repair, honored with the Ethica Award at the 2024 edition of #europcr. Ottavio Alfieri discusses his journey to becoming a cardiac surgeon, the genesis of...
Mastering the future of PCI with drug-coated balloons
16 May 2024 – From EuroPCR 2024
Join this session dedicated to drug-coated balloons (DCB) to delve into the evolution of angioplasty with DCBs in the U.S. Learn about the established standard of care, balancing efficacy and safety in treating in-stent restenosis (ISR). Gain insights into the fundamental principles of angioplasty with DCB...
What are the key considerations for first-time TAVI in a patient with long life expectancy?
15 May 2024 – From EuroPCR 2024
Interviewed by Dan Blackman, Philip Maccarthy discusses the rising trend of TAVI in younger patients and emphasizes optimizing first-TAVI procedure outcomes for long-term durability. He highlights considerations such as haemodynamics, low gradient, and minimizing paravalvular leak (PVL), as well as the importance of coronary access and...
Ahead of the curve - Innovate your treatment strategies for optimised clinical outcomes
14 May 2024 – From EuroPCR 2024
Watch this session to learn how to accurately interpret OCT-visualized dissections for an optimized PCI approach using drug-coated balloons (DCB) or drug-eluting stent (DES), to understand the critical role of sufficient and persistent sirolimus content in the vessel wall after using a sirolimus-coated balloon, to get...
When and how to treat the side branch in non-left main bifurcations?
16 May 2024 – From EuroPCR 2024
In this video, Jens Flensted Lassen and Thomas Cuisset discuss the importance of the side branch during bifurcation percutaneous coronary intervention (PCI). They emphasize that while there is no perfect solution for all patients, decisions must be tailored to each individual case, often influenced by the patient's...
Interventions for valvular disease: Highlights of EuroPCR 2024
16 May 2024 – From EuroPCR 2024
Christopher Cook hosts Nicolas Dumonteil and Bernard Prendergast as they share EuroPCR 2024 insights on valve disease interventions. Nicolas Dumonteil highlights record-breaking abstracts and cases, demonstrating expertise in TAVI, mitral, and tricuspid procedures. Bernard Prendergast emphasizes LIVE cases, especially in complex TAVI scenarios, reflecting everyday practice. Both stress...
A new horizon in IVUS-guided PCI of calcified stenoses with artificial intelligence
15 May 2024 – From EuroPCR 2024
In this session, observe the enhanced user-friendliness of IVUS-guided complex PCI with improved AI algorithms, recognize the importance of combining experience with advanced knowledge of tools and techniques for optimal PCI outcomes in heavily calcified stenoses, and understand how tailoring drug-eluting devices for calcified lesions can...
After ORBITA 2, what is the role of PCI in the contemporary management of patients with angina and coronary disease?
16 May 2024 – From EuroPCR 2024
Emanuele Barbato interviews Rasha Al-Lamee, the principal investigator of the ORBITA 2 trial, about the current role of percutaneous coronary intervention (PCI). Unlike ORBITA 1, ORBITA 2 focused on the effects of angioplasty as a monotherapy, without prior anti-angina treatment. The results showed that angioplasty improved symptoms...
What are the challenges for TAVI in bicuspid disease?
16 May 2024 – From EuroPCR 2024
Raj Makkar and Didier Tchétché address the complexities of bicuspid aortic valve disease, defining ideal candidates for TAVI or replacement and reviewing the NOTION-2 trial, which randomized younger, low-risk patients—including a significant number with bicuspid valves—to TAVI versus surgery. They highlight the importance of embolic protection...
Clinical experience with DurAVR THV: a new class, biomimetic TAVI
16 May 2024 – From EuroPCR 2024
Join Azeem Latib, Christopher Meduri, and Nicolas Van Mieghem as they explore the history of cutting-edge tissue science in the TAVI space. Learn about the development of a biomimetic aortic valve design and insights from the DurAVR FIH study on this balloon-expandable platform. Discover the link...
